aTyr Pharma (471A) Stock Statistics & Valuation Metrics
Total Valuation
aTyr Pharma has a market cap or net worth of EUR 10.81M. The enterprise value is EUR 12.22M.
- Market Cap
- EUR 10.81M
- Enterprise Value
- EUR 12.22M
Share Statistics
aTyr Pharma has 2,452,186 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,452,186
- Owned by Insiders
- 2.55%
- Owned by Institutions
- 19.11%
Financial Efficiency
aTyr Pharma’s return on equity (ROE) is -1.10 and return on invested capital (ROIC) is -96.45%.
- Return on Equity (ROE)
- -1.10
- Return on Assets (ROA)
- -0.79
- Return on Invested Capital (ROIC)
- -96.45%
- Return on Capital Employed (ROCE)
- -0.98
- Revenue Per Employee
- 3,275.862
- Profits Per Employee
- -1.28M
- Employee Count
- 58
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of aTyr Pharma is -0.20. aTyr Pharma’s PEG ratio is -0.01.
- PE Ratio
- -0.20
- PS Ratio
- 63.76
- PB Ratio
- 0.25
- Price to FCF
- -0.22
- Price to Operating Cash Flow
- -0.22
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, aTyr Pharma had revenue of 190.00K and earned -74.12M in profits. Earnings per share was -32.00.
- Revenue
- 190.00K
- Gross Profit
- -1.36M
- Operating Income
- -77.63M
- Pretax Income
- -74.12M
- Net Income
- -74.12M
- EBITDA
- -72.56M
- Earnings Per Share (EPS)
- -32.00
Cash Flow
In the last 12 months, operating cash flow was -54.54M and capital expenditures -279,000, giving a free cash flow of -54.82M billion.
- Operating Cash Flow
- -54.54M
- Free Cash Flow
- -54.82M
- Free Cash Flow per Share
- -22.36
Dividends & Yields
aTyr Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -452.53%
- Earnings Yield
- -502.05%
Stock Price Statistics
- Beta
- 1.04
- 52-Week Price Change
- -99.21%
- 50-Day Moving Average
- 8.92
- 200-Day Moving Average
- 17.35
- Relative Strength Index (RSI)
- 29.94
- Average Volume (3m)
- 336
Important Dates
aTyr Pharma upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
aTyr Pharma as a current ratio of 5.30, with Debt / Equity ratio of 17.83%
- Current Ratio
- 5.30
- Quick Ratio
- 5.30
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, aTyr Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
aTyr Pharma EV to EBITDA ratio is -0.12, with an EV/FCF ratio of -0.13.
- EV to Sales
- 38.17
- EV to EBITDA
- -0.12
- EV to Free Cash Flow
- -0.13
- EV to Operating Cash Flow
- -0.13
Balance Sheet
aTyr Pharma has EUR 57.42M in cash and marketable securities with EUR 11.30M in debt, giving a net cash position of EUR 46.12M billion.
- Cash & Marketable Securities
- EUR 57.42M
- Total Debt
- EUR 11.30M
- Net Cash
- EUR 46.12M
- Net Cash Per Share
- EUR 18.81
- Tangible Book Value Per Share
- EUR 19.82
Margins
Gross margin is -11967.89%, with operating margin of -33609.47%, and net profit margin of -32003.68%.
- Gross Margin
- -11967.89%
- Operating Margin
- -33609.47%
- Pretax Margin
- -32005.26%
- Net Profit Margin
- -32003.68%
- EBITDA Margin
- -31473.68%
- EBIT Margin
- -32306.32%
Analyst Forecast
The average price target for aTyr Pharma is EUR 35.70, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 35.70
- Price Target Upside
- 15286.27% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 27.06%